Testimony on Rilonacept (ARCALYST) to the FDA’s Arthritis Advisory Committee

Public Citizen strongly opposes the FDA’s approval of rilonacept for the prevention of gout flares because the drug provides no unique advantages over current treatment options and has known risks of serious infections and signals related to malignancies and adverse cardiovascular events.

View as PDF

View the press release